New drug PB shows promise for slowing excessive urination in kidney patients
NCT ID NCT05190744
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether the medication PB can safely reduce excessive urination in people with certain kidney diseases, including inherited nephrogenic diabetes insipidus, lithium-induced diabetes insipidus, and polycystic kidney disease treated with tolvaptan. Researchers measured changes in urine concentration and daily urine output over time. The study enrolled 36 adults and was completed in Phase 2.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACQUIRED NEPHROGENIC DIABETES INSIPIDUS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Mayo Clinic
Jacksonville, Florida, 32224, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can brain training lift the weight of depression in kidney disease?
- Thyroid hormones may hold clues to kidney disease progression
- Could zapping kidney nerves tame tough blood pressure in polycystic kidney disease?
- New study links blood markers to kidney disease progression in ADPKD
- Diabetes drug metformin tested as new weapon against kidney disease
- Parkinson's drug repurposed to fight kidney disease?